文献速递妇科

三氮烯化合物CT913对卵巢癌细胞的体外作用及其与PARP抑制剂奥拉帕尼的协同相互作用

The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib.
PubMed 文献 · Gynecol Oncol · 2020-09-23

本研究在卵巢癌细胞系中体外评价新型三氮烯衍生物CT913及其代谢物CT913-M1的作用,并与PARP抑制剂奥拉帕尼联用。CT913以剂量依赖方式降低铂敏感和铂耐药细胞活力,IC50在较高微摩尔范围(553-1083 μM),代谢物CT913-M1活性最高强69倍(IC50 8-138 μM)。CT913在BRCA1缺陷细胞中表现合成致死,并与奥拉帕尼协同,不依赖BRCA1突变状态。

要点

  • CT913剂量依赖性降低铂敏感和铂耐药卵巢癌细胞活力,IC50为553-1083 μM。
  • 代谢物CT913-M1活性最高强69倍,长期处理时IC50为8-138 μM。
  • CT913与奥拉帕尼协同,不依赖BRCA1突变状态,并可诱导CDKN1A转录。

核心结论

  • 本研究首次提示新型三氮烯药物CT913可作为增强药物以扩展PARP抑制剂的治疗谱。

研究设计与样本

  • 体外研究,在选定的卵巢癌细胞系面板中应用药物表征试验包括RNA-Seq。

主要发现

  • CT913处理在铂敏感和铂耐药卵巢癌细胞系中呈剂量依赖性降低细胞活力,IC50在较高微摩尔范围(553-1083 μM)。
  • 代谢物CT913-M1活性最高强69倍,尤其在长期处理时(IC50范围8-138 μM)。
  • 两种药物均未使细胞对顺铂敏感。
  • CT913在BRCA1缺陷卵巢癌细胞中表现合成致死,提示同源重组修复缺陷增强其效应。
  • CT913与奥拉帕尼显示协同相互作用,不依赖BRCA1突变状态。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Extending the therapeutic spectrum of PARP-inhibitors (PARPi) beyond BRCA1-deficiency and/or overcoming PARPi-resistance is of high clinical interest. This is particularly true for the identification of innovative therapeutic strategies for ovarian cancer, given the recent advances in the use of PARPi in clinical practice. In this regard, the combination of PARPi with chemotherapy is a possible strategy for defining new therapeutic standards. In this study, we analyzed the therapeutic effect of novel triazene derivatives, including the drug CT913 and its metabolite CT913-M1 on ovarian cancer cells and describe their interaction with the PARPi olaparib. METHODS: In vitro assays for drug characterization including RNA-Seq were applied in a selected panel of ovarian cancer cell lines. RESULTS: CT913 treatment conferred a dose-dependent reduction of cell viability in a set of platinum-sensitive and platinum-resistant ovarian cancer cell lines with an IC50 in the higher micromolar range (553-1083 μM), whereas its metabolite CT913-M1 was up to 69-fold more potent, especially among long-term treatment (IC50 range: 8-138 μM). Neither of the drugs sensitized for cisplatin. CT913 conferred synthetic lethality in BRCA1-deficient ovarian cancer cells, indicating that its effect is augmented by a deficiency in homologous recombination repair (HR). Furthermore, CT913 showed a synergistic interaction with olaparib, independently of BRCA1 mutational status. CT913 strongly induced CDKN1A transcription, suggesting cell cycle arrest as an early response to this drug. It moreover downregulated a variety of transcripts involved in DNA-repair pathways. CONCLUSIONS: This is the first study, suggesting the novel triazene drug CT913 as enhancer drug for extending the therapeutic spectrum of PARPi.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Wichmann C, Klotz DM, Zeiler HJ, et al. The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib. Gynecol Oncol. 2020. PMID: 32980128. doi:10.1016/j.ygyno.2020.09.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。